24 August 2024
: Case report 
Bifidobacterium Bloodstream Infection in a Lymphoma Patient Undergoing Chemotherapy: A Case Study and Implications for Probiotic Use
Unusual clinical course, Diagnostic / therapeutic accidents, Unexpected drug reaction
Osamu Imataki
1ABCDEFG*, Makiko Uemura 1ABCDEFG
DOI: 10.12659/AJCR.944687
Am J Case Rep 2024; 25:e944687
Table 1. The drug sensitivity results for isolated B. breve in this case.
| Antimicrobial drug | MIC susceptibility |
|---|---|
| ABPC | I |
| ABPC/SBT | I |
| TAZ/PIPC | I |
| CPZ/SBT | I |
| CTM | R |
| CMZ | I |
| FMOX | I |
| IPM/CS | I |
| MEPM | R |
| CLDM | S |
| MINO | S |
| LVFX | I |
| ABPC – ampicillin; CLDM – clindamycin; CMZ – cefmetazole; CPZ – cefoperazone; CS – cilastatin; CTM – cefotiam; FMOX – flomoxef; IPM – imipenem; LVFX – levofloxacin; MEPM – meropenem; MINO – minocycline; PIPC – piperacillin; SBT – sulbactam; TAZ – tazobactam; MIC – minimum inhibitory concentration; S – susceptible; I – susceptible, increased exposure; R – resistant. | |